Sucampo Pharmaceuticals, Inc. Class A
(NASDAQ : SCMP)

( )
SCMP PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
Loading SCMP News...
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson
-0.95%135.040.6%$889.69m
PFEPfizer Inc.
-0.76%33.780.8%$740.70m
MRKMerck & Co., Inc.
-0.55%65.560.6%$621.72m
BMYBristol-Myers Squibb Company
-1.78%55.911.4%$478.94m
ABBVAbbVie, Inc.
-0.47%72.402.1%$442.32m
LLYEli Lilly and Company
-1.46%83.051.0%$302.49m
NVSNovartis AG Sponsored ADR
-0.50%85.320.2%$169.46m
AZNAstraZeneca PLC Sponsored ADR
-1.65%34.571.3%$130.25m
GSKGlaxoSmithKline plc Sponsored ADR
-0.39%43.900.2%$120.16m
SNYSanofi Sponsored ADR
-0.41%49.390.2%$91.25m
NVONovo Nordisk A/S Sponsored ADR Class B
-1.96%43.520.1%$86.71m
LCILannett Company, Inc.
-0.97%20.5038.7%$11.32m
SCMPSucampo Pharmaceuticals, Inc. Class A
-3.26%10.4014.4%$4.62m
AKTXAkari Therapeutics Plc Sponsored ADR
-5.11%5.012.2%$0.38m
EPIXESSA Pharma Inc
2.36%0.570.0%$0.05m

Company Profile

Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company, which is engaged in developing, identifying, acquiring and bringing medicines that meet unmet medical needs. It focuses on gastroenterology, ophthalmology, and oncology-related disorders. The company's product pipeline includes AMITIZA for the treatment of chronic idiopathic constipation in adults; irritable bowel syndrome with constipation in adult women; opioid-induced constipation in patients with chronic non-cancer pain; chronic constipation; and pediatric functional constipation. Its product pipeline also consists of Unoprostone Isopropyl, which is in Phase III trial for the treatment of retinitis pigmentosa and in pre-clinical stage for the treatment of geographic atrophy; and Cobiprostone that has completed Phase Ib trial for the treatment of oral mucositis, as well as in Phase II trial for the treatment of non-erosive reflux diseases. Sucampo Pharmaceuticals was founded by Dr. Ryuji Ueno and Dr. Sachiko Kuno on December 5, 1996 and is headquartered in Bethesda, MD.,06559T-E